Skip to main content
Download PDF

A clinical study of topical treatment for thyroid-associated ophthalmopathy with dry eye syndrome

BMC Ophthalmology volume 23, Article number: 72 (2023) Cite this article

Abstract

Introduction

Clinically, thyroid-associated ophthalmopathy (TAO) patients were suffered from dry eye syndrome. Only a few relevant studies were about this topic. Our study was determined to provide high-level evidence for the treatment of TAO with dry eye syndrome.

Purpose

To compare the clinical effects of vitamin A palmitate eye gel and sodium hyaluronate eye drop forTAO patients with dry eye syndrome.

Methods

The study was conducted in the Ophthalmology Department of the Ninth People’s Hospital Affiliated with the Medical College of Shanghai Jiao Tong University from May to October 2020. A total of 80 mild or moderate-to-severe TAO patients with dry eye syndrome were randomly divided into two groups. The disease stages of all subjects were inactive. Patients in group A were treated with vitamin A palmitate eye gel three times/day for one month and sodium hyaluronate eye drop in group B. The index including break-up time (BUT) and Schirmer I test (ST), corneal fluorescence staining (FL), ocular surface disease index (OSDI), and adverse reactions were recorded by the same clinician at baseline and 1 month after treatment. The data were analyzed by SPSS 24.0.

Results

Finally, 65 subjects completed the treatment. The average age of the patients in Group A was 38.1 ± 11.4 years, and that in Group B was 37.26 ± 10.67 years. 82% of the subjects in group A were female and 74% in group B. There was no significant difference between the two groups at baseline, including the value of ST, BUT, OSDI, and FL grade. After the treatment, the effective rate was 91.2% in group A, of which the value of BUT and FL grade was significantly improved (P < 0.001). The effective rate in group B was 67.7%, of which the value of OSDI score and FL grade was significantly improved (P = 0.002). In addition, the BUT value of group A was significantly longer than that of group B (P = 0.009).

Conclusion

InTAO patients with dry eye syndrome, vitamin A palmitate gel and sodium hyaluronate eye drop improved the dry eye and promoted corneal epithelial repair. Vitamin A palmitate gel improves the stability of tear film, while sodium hyaluronate eye drop improves patients’ subjective discomfort.

Peer Review reports

Introduction

Thyroid-associated ophthalmopathy (TAO), which also called Graves’ ophthalmopathy (GO) or Thyroid eye disease (TED), is an autoimmune disease that usually occurs in patients with Graves’ disease or autoimmune thyroiditis [1,2,3,4,5,6].

TAO patients suffer from exophthalmos, eyelid retraction and eye movement disorder [7]. Dry eye syndrome is one of the most common reasons for eye discomfort in patients with TAO, with a high incidence of 65%-85% [8,9,10]. Possible causes of dry eye are as follows. Firstly, the inflammatory reaction of the lacrimal gland, the increase in incomplete blink rate and the loss of the meibomian gland can influence the secretion of tear and alter the tear composition [11,12,13,14]. In the case of the lacrimal gland of TAO patients, local lymphocyte infiltration may increase its volume, altering the tear composition [15]. The levels of inflammatory proteins and cytokines increase in TAO patients’ tears [16,17,18]. Secondly, exophthalmos and eyelid retraction increases the ocular surface exposure, resulting in tear evaporation and elevated osmotic pressure [19]. In addition, Stellwag’s sign and aggravated eye movement disorder can further damage the cornea and conjunctiva [15]. TAO patients had lower superficial epithelial cell density in the superior bulbar conjunctiva, increased Langerhans cell density, and reduced goblet cell density. A high degree of squamous metaplasia was revealed in the conjunctival epithelium of TAO patients [14]. Corneal sensitivity is also affected. TAO patients had fewer epithelial corneal cells, lower sub-basal nerve density, and more stromal corneal cells compared to the normal subjects [20]. Therefore, TAO leads to dry eye syndrome with complex pathogenesis. Currently, only a few relevant studies are available on the treatment of TAO with dry eye syndrome, albeit controversial and not a distinct standardized treatment regimen [21]. Therefore, this study enrolled TAO patients with dry eye syndrome and randomly categorized them into Group A and Group B; vitamin A palmitate eye gel or sodium hyaluronate eye drop was applied three times a day independently to evaluate the efficacy and safety of the treatment.

Materials and methods

This was a prospective, randomized clinical study. A total of 80 mild or moderate-to-severe TAO patients (80 eyes) with dry eye syndrome were selected from the Ophthalmology Department of the Ninth People’s Hospital Affiliated to the Medical College of Shanghai Jiao Tong University from May to October 2020. The disease stages of all subjects were inactive. The severely affected eye in each patient was considered in the study. The inclusion criteria were as follows: ① Diagnosed as mild or moderate-to-severe TAO and the disease stage was inactive.; ② Diagnosed as dry eye syndrome. The exclusion criteria were as follows: ① Suffering from other ophthalmic diseases affecting the ocular surface; ② Suffering from autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, and Sjögren’s syndrome; ③ Previous ocular trauma or surgery; ④ Extremely severe TAO; ⑤ Allergic to drug ingredients. The content of this study was approved by the medical ethics committee of our hospital (approval No. sh9h-2019-t343-2, approved on March 18th, 2020) and registered in the Chinse clinical trial registry (Registration no. chictr2000033874, approved on 15/06/2020). Informed consent was signed by all subjects.

TAO was diagnosed according to the Bartley standard [22]. If eyelid retraction was detected, one of the following three signs could be diagnosed as TAO: ① Exophthalmos; ② History of thyroid dysfunction; ③ Extraocular muscle involvement. If eyelid retraction was not found, all the three conditions should be fulfilled: ① History of thyroid dysfunction; ② Combined with exophthalmos, extraocular muscle involvement, or visual dysfunction; ③ Excluding eyelid retraction, exophthalmos, and eye movement disorder caused by other eye diseases.

Mild TAO was defined as patients who could not meet the diagnostic criteria of moderate-to-severe TAO. Moderate-to-severe TAO was defined if a patient had no visual impairment but at least two of the following manifestations: ① Eyelid retraction: upper lid margin to reflex distance (MRD-1) was > 5 mm or a lower lid margin to reflex distance (MRD-2) was > 6 mm. ② Moderate-to-severe soft tissue damage (one of the following: moderate-to-severe eyelid swelling or moderate-to-severe conjunctival congestion); ③ At least 3 mm over the normal value of proptosis (Hertel exophthalmos of any eye ≥ 17 mm); ④ Stable or intermittent diplopia.

Extremely severe TAO was defined as patients with compressive optic neuropathy (DON) and/or severe exposure keratopathy.

The following was the judgment criteria for active and inactive TAO [23]. The clinical activity score (CAS) was used to evaluate active and inactive TAO. The scale comprised seven items, including eyelid edema, eyelid congestion, conjunctival congestion, conjunctival edema, lacrimal caruncle redness and swelling, spontaneous retrobulbar pain, and pain during gaze or eye movement. Each of the items was scored 1 point, < 3 points as inactive period, and ≥ 3 points as the active period.

TAO with dry eye syndrome was defined as fulfilling any of the following items based on the diagnosis of TAO [24]: ① having one of the subjective symptoms (visual fatigue, discomfort, foreign body, dryness, burning, and visual acuity fluctuation) and Schirmer I test (ST) ≤ 10 mm; ② One of the subjective symptoms and break-up time (BUT) ≤ 10 s; ③ Positive fluorescein staining of keratoconjunctiva.

The chemical composition

0.1% sodium hyaluronate eye drop: Sodium hyaluronate of 2 million to 3 million Daltons is the main component. The concentration is 0.1% and it does not contain preservatives. Inherent viscosity is 2.4–3.2m3/kg.

Vitamin A palmitate eye gel: Vitamin A palmitate of 524.87 Daltons is the main component. The concentration is 0.8 mg/g and it contains preservatives. Inherent viscosity is 3.2–4.2m3/kg.

Sample Size

In the pre-experiment, 10 patients who applied Vitamin A palmitate eye gel got an effective rate of 60% in improving dry eye while 10 who applied 0.1% sodium hyaluronate eye drop got 30%. We let the inspection level α = 0.049, inspection efficiency 1- β = 0.80. Considering the possible loss of follow-up rate as 20%, the total sample size of this study was 80 and 40 in each group.

In this study, 80 patients (80 eyes) were randomly divided into Group A and Group B by the envelope method. Vitamin A palmitate eye gel was applied in Group A three times/day, one drop each time. Group B was given 0.1% sodium hyaluronate eye drop three times/day, one drop each time. The effect was evaluated 1 month after drug administration. During the treatment, other topical eye drugs were not allowed.

The following data of subjects were collected at baseline and after 1 month of treatment. In consideration of the actual situation, clinical data were collected three days before or after one month was allowed. Generally, gel or eye drops were not used on the day of measurement, and the measurement time was at the same time of the day at baseline or post treatment.

ST

The inverted end of the long tear detection filter paper was placed about 5 mm into the outer 1/3rd of the subject's lower eyelid conjunctival sac without ocular surface anesthesia, and the subject was asked to close his eyes gently. After 5 min, the filter paper was taken down, and the ST value was recorded.

BUT

Corneal topography (Keratograph 5 M, type 77,000, Germany) was applied. After the subject placed his head in the specified area, the BUT function option of the software, OCULUS Keratograph, was selected. The subject was instructed to look forward without blinking. The value of BUT was obtained after the examination.

Fluorescence staining (FL)

The range of fluorescein staining was observed under the cobalt blue light of the slit lamp microscope after placing the 2% sodium fluorescein staining test paper into the subject’s conjunctival sac of the lower eyelid. The cornea was divided into four quadrants: supratemporal, infratemporal, supranasal, and infranasal. The score was evaluated in every quadrant. The scoring criteria were as follows: 0 for no coloring, 1 for scattered punctate coloring, 2 for diffuse punctate coloring, and 3 for massive coloring. The sum of the scores in each quadrant constituted the corneal FL score with a total of 0–12 points.

Ocular surface disease index (OSDI)

The subjects were required to answer 12 questions, and each question was scored 0–4 points [25]. Nonetheless, the subject could refuse to answer some of the questions. The total score was multiplied by 25 and then divided by the number of questions answered to obtain the final score.

Effective rate

The effective rate was if any of the following three conditions were satisfied. ① The value of ST was improved by 2 mm after treatment; ② The value of BUT was improved by 2 s after treatment; ③ The FL was decreased by 1 point after treatment [26].

Statistical analysis

The statistician generated a random sequence, and the clinician who made the evaluation was blind to the grouping. The data were statistically analyzed using SPSS 24.0. The continuous data obeying the normal distribution were expressed as mean ± standard deviation, and non-normal data were represented as median (interquartile range). The paired sample t-test or Wilcoxon signed-rank test was used for the comparison between the two groups of paired samples, and the independent sample t-test or Mann–Whitney U test was used for the comparison between the two groups of independent samples. Categorical data were described as the number of cases (percentage), and the chi-square test was used for intergroup comparison. P < 0.05 indicated statistically significant difference.

Results

A total of 80 mild or moderate-to-severe TAO patients (80 eyes) with dry eye syndrome were enrolled in this study. The disease stages of all subjects were inactive. Subsequently, 6 patients in Group A and 9 patients in Group B were lost to follow-up (Fig. 1). The other patients completed the treatment according to the plan. The average age of the patients in Group A was 38.10 ± 11.40 years, and that in Group B was 37.26 ± 10.67 years. No significant difference was observed between the two groups in age, gender, clinical activity score (CAS), exophthalmos, MRD-1, MRD-2, visual acuity, intraocular pressure, the values of ST, BUT, and OSDI, and FL grade (P > 0.05, Table 1).

Fig. 1
figure 1

Study flow chart

Full size image
Table 1 Baseline conditions of the two groups before treatment
Full size table

In Group A, ST increased from 8.61 ± 6.34 mm to 9.13 ± 7.1 mm, and the score of the OSDI scale improved from 19.60 (9.30–43.13) to 14.58 (6.67–31.25) (P > 0.05). In addition, BUT increased from 6.38 ± 4.48 s to 9.84 ± 3.76 s (P < 0.001) and the FL grade improved from 2 (1–5) to 1 (0–2) (P < 0.001). After 1-month of treatment, the stability of tear film improved and the corneal epithelial injury was repaired.

In Group B, ST increased from 5.78 ± 4.81 mm to 6.37 ± 5.23 mm and BUT increased from 6.28 ± 3.85 s to 7.17 ± 4.08 s, with no significant difference (P > 0.05). The score of OSDI scale improved from 21.87 (8.33–43.18) to 9.09 (5.55–25) (P = 0.002), and the FL grade improved from 2 (1–2) to 1 (0–2) (P = 0.002). Subsequently, the subjective discomfort of the patients improved, and the corneal epithelial injury was repaired. Also, a significant difference was detected in BUT after treatment (P = 0.009), but no difference in ST, OSDI, and FL grade between the two groups (Tables 2 and 3).

Table 2 Comparison of dry eye indexes between the two groups after treatment
Full size table
Table 3 Comparison of dry eye indexes in two groupsbefore and after treatment
Full size table

Among the subjects, 17 patients had an ST increase > 2 mm, 30 had a BUT enhancement > 2 mm, and 36 had an FL grade improvement > 1 point. The total effective rate was 80.0% (52/65). In group A, 10 patients had an ST increase > 2 mm, 21 had a BUT enhancement > 2 mm, and 21 had a FL grade improvement > 1 point, with an effective rate of 91.2% (31/34). In group B, 7 patients had an ST increase > 2 mm, 9 had a BUT enhancement > 2 mm, and 13 had an FL grade improvement > 1 point, with an effective rate of 67.7% (21/31). Strikingly, a significant difference was observed between the two groups (P = 0.018).

In terms of safety, only one case of drug allergy occurred in Group A, and after stopping the application of the eye gel, conjunctival hyperemia disappeared in 1 day without any complications.

Discussion

Dry eye syndrome is an important factor that causes eye discomfort in TAO patients clinically, which is closely related to the increase of tear evaporation and osmotic pressure caused by the increase of ocular surface exposure, the change of tear composition caused by eye inflammation, and eye movement disorders. However, the treatment for TAO with dry eye syndrome has not been standardized, and there are few articles on related issues. Therefore, this article aimed to provide high-quality clinical evidence for the treatment of TAO patients with dry eye syndrome.

The first problem was the selection of research objects. The ocular manifestations of patients with extremely severe TAO or with active TAO are still changing, so it is difficult to distinguish whether the effect of drug treatment is affected by the development of the disease. Therefore, we choose patients with mild or moderate-to-severe TAO patients as subjects and the disease stages of all subjects were inactive. At baseline, we evaluated the patients’ age and gender. In our study, the average age of the subjects was slightly lower than the results of some previous study [27, 28]. Dolman et al. demonstrated that the risk factors of DON included advancing age and male gender, which might explain this problem [29]. There was no difference in age and exophthalmos between the two groups, and the results were consistent with those mentioned in other studies [28, 30,31,32]. In addition, the value of MRD, CAS, visual acuity and IOP at baseline all showed no difference between the two groups.

ST and BUT are objective indexes to evaluate the dry eye, which reflect the stability of tear film and basic tear secretion. These two indicators have decreased in varying degrees in TAO patients with dry eye syndrome because of the increase of exposure factors, the occurrence of inflammation and the reduction of tear secretion. The ST of Group A increased from 8.61 ± 6.34 mm to 9.13 ± 7.1 mm (P = 0.402) and BUT increased from 6.38 ± 4.48 s to 9.84 ± 3.76 s (P < 0.001) after treatment, while ST of Group B increased from 5.78 ± 4.81 mm to 6.37 ± 5.23 mm and BUT increased from 6.28 ± 3.85 s to 7.17 ± 4.08 s (P > 0.05). It indicated that vitamin A palmitate eye gel was superior to sodium hyaluronate eye drop in improving the tear film stability of TAO patients with dry eye syndrome, which could take effect in 1 month. Sodium hyaluronate is a commonly used artificial tear drug in the clinic. It has good viscoelasticity and hygroscopicity, and the carboxyl and hydroxyl groups in the molecular structure produce hydrogen bonds with water with significant water retention. For other dry eye syndromes, such as those appearing after cataract surgery, sodium hyaluronate eye drop improves the patients' symptoms and signs [33,34,35]. Vitamin A palmitate gel maintains the stability of the tear film, increases the density of goblet cells, and promotes the secretion of goblet cells and lacrimal gland cells [21, 36,37,38]. It also promotes intercellular connections and reverses keratosis of corneal epithelial cells. Vitamin A palmitate eye gel reduces the incidence of dry eye syndrome after strabismus surgery and increases the density of goblet cells, improving dry eye caused by prostaglandin analog [39, 40]. Altiparmak et al. demonstrated found that 6 months after using artificial tear drops, ST of TAO patients with dry eye syndrome increased from 3.73 ± 1.85 mm to 10.73 ± 5.71 mm and BUT increased from 6.21 ± 1.73 s to 12.9 ± 3.96 s [41]. However, applying artificial tears and cyclosporine A increased ST from 3.32 ± 1.99 mm to 6.68 ± 4.42 mm and increased BUT from 6.36 ± 2.02 s to 10.92 ± 0.76 s. We found that the improvement of ST and BUT in our study was lesser than that reported by Altiparmak et al.. These phenomena might be caused by the short period of treatment time. We speculated that prolonged medication could achieve significant results. Although vitamin A palmitate eye gel can increase the number of goblet cells, it was not sufficient for a significant difference in ST in a short-term observation of 1 month. The inflammatory reaction of the lacrimal gland in TAO patients reduced the secretion of tears, which might not be improved by vitamin A palmitate eye gel or sodium hyaluronate eye drop. Also, the exposure factors were not resolved, which might explain why ST did not increase significantly in both groups.

FL examination can be used to assess the degree of corneal epithelial injury. Due to the increase of ocular surface exposure and exophthalmos, the FL grade of TAO patients with dry eye syndrome would increase as the baseline data showed. A past study showed that the topical use of Rebamipide for 1 month improves the upper limbal keratoconjunctivitis of TAO patients and repairs the corneal injury [42]. In our study, according to corneal fluorescein staining, applying vitamin A palmitate eye gel or sodium hyaluronate eye drop significantly reduced the FL grade, promoting the repair of corneal epithelial cells. However, the number of patients whose FL grade improved > 1 point after treatment in Group A was 21 and 9 in Group B. For patients with dry eye syndrome, sodium hyaluronate eye drop improves the FL grade. The synthesis of cytokine receptors and glycoproteins is promoted by vitamin A palmitate gel that can shorten the epithelial healing time and improve dry eye [39, 43, 44]. A previous study demonstrated that vitamin A palmitate eye gel combined with sodium hyaluronate eye drop can relieve the symptoms of dry eye patients and also significantly reduce FL grade and the level of inflammatory factors in tears [21]. This phenomenon that FL grade improved more in group A after treatment could be attributed to the gelatinous nature of vitamin A palmitate eye gel, prolonging the retention time in the conjunctival sac. This, in turn, promoted the repair of corneal epithelium.

The OSDI scale evaluates the subjective feeling of the patients [45]. TAO patients have reduced tear secretion, decreased tear film stability, damaged corneal epithelium, and can feel discomfort, such as foreign body, fatigue, burning, and decreased vision, which will increase their OSDI score [10, 22]. Gürdal et al. demonstrated that after 2 months of topical cyclosporine A treatment, OSDI score decreased significantly (P = 0.001) [46, 47]. In our study, the OSDI score of Group B was significantly lower after treatment than before the treatment, suggesting that the patient's subjective symptoms were improved. Although the OSDI score of Group A improved, no significant difference was detected after treatment compared to that at baseline. Sodium hyaluronate is conducive to improving the congestion of bulbar conjunctiva and reducing the local inflammatory reaction and negative psychological emotion of patients with high safety [48, 49]. Retinol palmitate ophthalmic solution has also been proven beneficial to the objective signs and subjective symptoms of dry eye syndrome [50]. Though both groups had an improved OSDI score, significant differences existed only in group B. This might be due to a slight pain in the eyes of some patients after using vitamin A palmitate eye gel, which affected the feelings of patients. The gel might influence the visual acuity of subjects after application. Herein, we recorded one case of drug allergy in Group A, which was recovered after drug withdrawal.

Overall, the efficiency of vitamin A palmitate eye gel on TAO with dry eye syndrome was significantly higher than that of sodium hyaluronate eye drop. Both improved corneal epithelial injury and index for evaluating the dry eye. Therefore, these two drugs could be utilized clinically to improve the dry eye syndrome of TAO patients. Nevertheless, the present study has some deficiencies. It is a single-center study with a small sample size and short observation time. TAO patients with different disease stages or grading may have varied responses to the topical eye drops. In addition, 15 subjects in this study missed their follow-up due to the COVID-19 pandemic. However, this study still has high credibility because the initial sample size included a lost visit rate of only 20%. Further studies should be focused on other drugs such as sodium hyaluronate eye drops with higher concentration and the superimposed use of drugs to explore the local treatment scheme of TAO with dry eye syndrome. In the past studies, the description of the role of cyclosporine in TAO patients with dry eye syndrome had the opposite conclusion [41, 46, 47]. Clinical data, such as the tear osmolarity measurement, the number of goblet cells, corneal sensitivity, and corneal nerve fiber density, biomarkers, can be added to future studies, providing evidence for the standard treatment for TAO with dry eye syndrome [51, 52].

Conclusion

Both 0.1% sodium hyaluronate eye drop and vitamin A palmitate gel can be used in the treatment of TAO with dry eye syndrome. Both drugs promote corneal epithelial repair; vitamin A palmitate eye gel can improve tear film stability, and sodium hyaluronate eye drop can improve the patients’ subjective symptoms. Thus, vitamin A palmitate eye gel is more effective than 0.1% sodium hyaluronate eye drop for treating TAO with dry eye syndrome.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

References

  1. Bartalena L. Prevention of Graves’ ophthalmopathy. Best Pract Res Clin Endocrinol Metab. 2012;26(3):371–9.

    Article  PubMed  Google Scholar 

  2. Longo DL, Smith TJ, Hegedüs L, et al. Graves Disease. N Engl J Med. 2016;375(16):1552–65.

    Article  Google Scholar 

  3. Huang Y, Wu Y, Zhang S, et al. Immunophenotype of lacrimal glands in Graves orbitopathy: Implications for the pathogenesis of Th1 and Th17 immunity. Thyroid. 2022;32:949–61.

  4. Fang SJ, Lu Y, Huang YZ, et al. Mechanisms That Underly T Cell Immunity in Graves’ Orbitopathy. Front Endocrinol (Lausanne). 2021;12:648732.

    Article  PubMed  Google Scholar 

  5. Fang SJ, Zhang S, Huang YZ, et al. Evidence for Associations Between Th1/Th17 “Hybrid” Phenotype and Altered Lipometabolism in Very Severe Graves Orbitopathy. J Clin Endocrinol Metab. 2020;6:6.

    Google Scholar 

  6. Huang YZ, Fang SJ, Li D, et al. The involvement of T cell pathogenesis in thyroid-associated ophthalmopathy. Eye (Lond). 2019;33:176–82.

    Article  CAS  PubMed  Google Scholar 

  7. Bartalena L, Tanda ML. Graves’ Ophthalmopathy. N Engl J Med. 2009;362(8):726–38.

    Google Scholar 

  8. Gürdal C, Saraç O, Genç I, et al. Ocular surface and dry eye in Graves’ disease. Curr Eye Res. 2011;36:8–13.

    Article  PubMed  Google Scholar 

  9. Ismailova DS, Fedorov AA, Grusha YO. Ocular Surface Changes in Thyroid Eye Disease. Orbit. 2013;32(2):87–90.

    Article  PubMed  Google Scholar 

  10. Wang P, Wei RL, Ma XY. Research Progress on the pathogenesis of thyroid associated ophthalmopathy complicated with dry eye. Chin J Pract Ophthalmol. 2016;34:657–60.

    Google Scholar 

  11. Song RH, Wang B, Yao QM, et al. Proteomics screening of differentially expressed cytokines in tears of patients with Graves’ ophthalmopathy. Endocr Metab Immune Disord Drug Targets. 2020;20:87–95.

    Article  CAS  PubMed  Google Scholar 

  12. Wu Y, Lu Y, Sun R, et al. Expression and clinical significance of α1-antitrypsin in thyroid-associated ophthalmopathy. J Shanghai Jiao Tong University (Med Sci). 2020;040(004):430–4.

    CAS  Google Scholar 

  13. Park J, Baek S, et al. Dry eye syndrome in thyroid eye disease patients: The role of increased incomplete blinking and Meibomian gland loss. Acta ophthalmologica. 2019;97:e800–6.

    Article  CAS  PubMed  Google Scholar 

  14. Wei Y, Chen W, Hu F, et al. In vivo confocal microscopy of bulbar conjunctiva in patients with Graves’ ophthalmopathy. J Formos Med Assoc. 2013;114(10):965–72.

    Article  PubMed  Google Scholar 

  15. Li YW, Wei J, Shang XL, et al. Clinical study of dry eye prevalence and tear film function and corneal status in patients with thyroid associated ophthalmopathy. Int Eye Sci. 2018;18(2):313–5.

    Google Scholar 

  16. Kishazi E, Dor M, Eperon S, et al. Differential profiling of lacrimal cytokines in patients suffering from thyroid-associated orbitopathy. Sci Rep. 2018;8(1):10792.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Chen Q. The expression of interleukin-15 and interleukin-17 in tears and orbital tissues of Graves ophthalmopathy patients. J Cell Biochem. 2019;120(4):6299–303.

    Article  CAS  PubMed  Google Scholar 

  18. Matheis N, Grus FH, Breitenfeld M, Knych I, et al. Proteomics differentiate between thyroidassociated orbitopathy and dry eye syndrome. Invest Ophthalmol Vis Sci. 2015;56(4):2649–56.

    Article  CAS  PubMed  Google Scholar 

  19. Gilbard JP, Farris RL. Ocular surface drying and tear film osmolarity in thyroid eye disease. Acta Ophthalmol. 1983;61(1):108–16.

    Article  CAS  Google Scholar 

  20. Villani E, Viola F, Sala R, et al. Corneal involvement in Graves’ orbitopathy: an in vivo confocal study. Invest Ophthalmol Vis Sci. 2010;51:4574–8.

    Article  PubMed  Google Scholar 

  21. Sun R, Zhou HF, Fan XQ. Ocular surface changes in Graves’ ophthalmopathy. Int J Ophthalmol. 2021;14:616–21.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Bartley GB, Gorman CA. Diagnostic criteria for Graves’ ophthalmopathy. Am J Ophthalmol. 1995;119(6):792–5.

    Article  CAS  PubMed  Google Scholar 

  23. Bartalena L, Baldeschi L, Boboridis K, et al. The 2016 European thyroid association/European group on Graves’ orbitopathy guidelines for the management of Graves’ orbitopathy. Eur Thyroid J. 2016;5(1):9–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Wolffsohn JS, Arita R, Chalmers R, et al. TFOS DEWS II Diagnostic Methodology report. Ocul Surf. 2017;15:539–74.

    Article  PubMed  Google Scholar 

  25. Dougherty BE, Nichols JJ, Nichols KK. Rasch analysis of the Ocular Surface Disease Index (OSDI). Invest Ophthalmol Vis Sci. 2011;52:8630–5.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Liu JY, Zhong Q. Clinical effect of vitamin A palmitate eye gel combined with sodium hyaluronate eye drop on xerophthalmia after cataract phacoemulsification. Shanghai YI YAO. 2020;41(21):4.

    CAS  Google Scholar 

  27. Lim N, Sundar G, Amrith S, et al. Thyroid eye disease: a Southeast Asian experience. Br J Ophthalmol. 2015;99(4):512.

    Article  PubMed  Google Scholar 

  28. Li Q, Ye H, Ding Y, et al. Clinical characteristics of moderate-to-severe thyroid associated ophthalmopathy in 354 Chinese cases. PLoS ONE. 2017;12(5):e0176064.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Dolman PJ. Dysthyroid optic neuropathy: evaluation and management. J Endocrinol Invest. 2021;44:421–9.

    Article  CAS  PubMed  Google Scholar 

  30. Bahn RS. Graves’ ophthalmopathy. N Engl J Med. 2010;362(8):726–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Du B, Wang Y, Yang M, et al. Clinical features and clinical course of thyroid-associated ophthalmopathy: a case series of 3620 Chinese cases. Eye. 2021;35(8):2294–301.

  32. Kozaki A, Inoue R, Komoto N, et al. Proptosis in dysthyroid ophthalmopathy: a case series of 10,931 Japanese cases. Optom Vis. 2010;87(3):200–4.

    Article  Google Scholar 

  33. Wen Y, Zhang XC, Chen MS, et al. Sodium hyaluronate in the treatment of dry eye after cataract surgery: a meta-analysis. Ann Palliat Med. 2020;9:927–39.

    Article  PubMed  Google Scholar 

  34. Takamura E, Tsubota K, Watanabe H, et al. A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients. Br J Ophthalmol. 2012;96:1310–5.

    Article  PubMed  Google Scholar 

  35. Park YL, Song JS, Choi CY, et al. A Randomized Multicenter Study Comparing 0.1%, 0.15%, and 0.3% Sodium Hyaluronate with 0.05% Cyclosporine in the Treatment of Dry Eye. J Ocul Pharmacol Ther. 2017;33:66–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Hiroshi T, Toshinari F, Koichi O, et al. Efficacy and safety of retinol palmitate ophthalmic solution in the treatment of dry eye: a Japanese Phase II clinical trial. Drug Des Dev Ther. 2017;11:1871–9.

    Article  Google Scholar 

  37. Gou JY, Li YL. Effect of vitamin a palmitate gel on dry eye after phacoemulsification and intraocular lens implantation. Chin J Pract Ophthalmol. 2013;31(9):1139–41.

    Google Scholar 

  38. Lu YY, Ren J, Ge XH. Effect of vitamin a palmitate ophthalmic gel adjunctive therapy on tear film stability and inflammatory cytokines in patients with dry eye. Int Eye Sci. 2018;18(6):4.

    Google Scholar 

  39. Cui X, Xiang J, Zhu W, et al. Vitamin a palmitate and Carbomer Gel Protects the Conjunctiva of Patients With Long-term Prostaglandin Analogs Application. J Glaucoma. 2016;25(6):487.

    Article  PubMed  Google Scholar 

  40. Yang SL, Guo WN, Gong YX, et al. Application of vitamin A palmitate eye gel and nurse value of Watson’s theory of caring in children with dry eye after strabismus surgery: a randomized trial. Transl Pediatr. 2021;10:2335–46.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Altiparmak UE, Acar DE, Ozer PA, et al. Topical cyclosporine A for the dry eye findings of thyroid orbitopathy patients. Eye (Lond). 2010;24:1044–50.

    Article  CAS  PubMed  Google Scholar 

  42. Takahashi Y, Ichinose A, Kakizaki H. Topical rebamipide treatment for superior limbic keratoconjunctivitis in patients with thyroid eye disease. Am J Ophthalmol. 2014;157:807-812.e2.

    Article  CAS  PubMed  Google Scholar 

  43. Jin HY, Yan T. Clinical observation of vitamin A Palmitate Eye Gel combined with Tobramycin Eye Drops in repairing of corneal epithelial defect. Int Eye Sci. 2019;19(02):138–40.

    Google Scholar 

  44. Tabuchi N, Toshida H, et al. Effect of Retinol Palmitate on Corneal and Conjunctival Mucin Gene Expression in a Rat Dry Eye Model After Injury. J Ocul Pharmacol Ther Official J Assoc Ocul Pharmacol Ther. 2017;33:24–33.

    Article  CAS  Google Scholar 

  45. Han KE, Yoon SC, Ahn JM, et al. Evaluation of dry eye and meibomian gland dysfunction after cataract surgery. Am J Ophthalmol. 2014;157(6):1144–50.

    Article  PubMed  Google Scholar 

  46. Gürdal C, Genç I, Saraç O, et al. Topical cyclosporine in thyroid orbitopathy-related dry eye: clinical findings, conjunctival epithelial apoptosis, and MMP-9 expression. Curr Eye Res. 2010;35:771–7.

    Article  PubMed  Google Scholar 

  47. Selter JH, Gire AI, Sikder S. The relationship between Graves’ ophthalmopathy and dry eye syndrome. Clin Ophthalmol. 2015;9:57–62.

    PubMed  Google Scholar 

  48. Shi W, Wang XY, Zhang T, et al. Therapeutic effects of 0. 3% sodium hyaluronate eye drops on mild or moderate dry eyes and its effect on BUT, SIt, conjunctival congestion degree of patients. Hebei Med J. 2021;43(5):3.

    Google Scholar 

  49. Chen Y, He L, Liu ZY. The effects of recombinant human epidermal growth factor gel combined with sodium hyaluronate eye drops on the stability of the tear film and the basal secretion of tears in patients with dry eye after phacoemulsification. Shi Yong Yi Yuan Lin Chuang Za Zhi. 2021;18(1):4.

    Google Scholar 

  50. Toshida H, Funaki T, Ono K, et al. Efficacy and safety of retinol palmitate ophthalmic solution in the treatment of dry eye: a Japanese Phase II clinical trial. Drug Des Devel Ther. 2017;11:1871–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Novack GD, Asbell P, Barabino S, Bergamini MVW, et al. TFOS DEWS II Clinical Trial Design Report. Ocul Surf. 2017;15(3):629–49.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Gilbard JP, Farris RL. Ocular surface drying and tear film osmolarity in thyroid eye disease. Acta Ophthalmol (Copenh). 1983;61(1):108–16.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the National Natural Science Foundation of China (81930024, 82071003, 82000879), the National Key R&D Program of China (2018YFC1106100, 2018YFC1106101), the Research Grant of the Shanghai Science and Technology Committee (20DZ2270800), the Sample Database Project of Shanghai Ninth People's Hospital (YBKB201901), and the Joint Innovation Team for Young Physicians of Shanghai Ninth People's Hospital (QC202002).

Funding

This work was supported by the National Natural Science Foundation of China (81930024, 82071003, 82000879), the National Key R&D Program of China (2018YFC1106100, 2018YFC1106101), the Research Grant of the Shanghai Science and Technology Committee (20DZ2270800), the Sample Database Project of Shanghai Ninth People's Hospital (YBKB201901), and the Joint Innovation Team for Young Physicians of Shanghai Ninth People's Hospital (QC202002).

Author information

Author notes

  1. Rou Sun and Muyue Yang contribute equally to this work.

Authors and Affiliations

  1. Department of Ophthalmology, Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China

    Rou Sun, Muyue Yang, Chenyi Lin, Yu Wu, Jing Sun & Huifang Zhou

Authors
  1. Rou Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Muyue Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chenyi Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yu Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jing Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Huifang Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Manuscript writing: Rou Sun, Muyue Yang; Implementation of the study: Rou Sun, Muyue Yang, Chenyi Lin, Yu Wu; Study design: Jing Sun, Huifang Zhou. The author(s) read and approved the final manuscript.

Corresponding authors

Correspondence to Jing Sun or Huifang Zhou.

Ethics declarations

Ethics and consent to participate

The content of this study was approved by the medical ethics committee of our hospital (approval No. sh9h-2019-t343-2, approved on March 18th, 2020). The study was carried out in accordance with the relevant guidelines. Written informed consents were obtained from all participants.

Consent for publication

Written consents were obtained from all participants.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sun, R., Yang, M., Lin, C. et al. A clinical study of topical treatment for thyroid-associated ophthalmopathy with dry eye syndrome. BMC Ophthalmol 23, 72 (2023). https://doi.org/10.1186/s12886-023-02805-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12886-023-02805-8

Keywords

BMC Ophthalmology

ISSN: 1471-2415

Contact us